FDA approves nasal drug delivery device for breakthrough treatment of depression
Aptar Pharma’s Bidose liquid system is designed for local or systemic delivery of drugs.
Aptar Pharma's Bidose nasal spray device has been approved by the FDA for a breakthrough therapy in the field of depression. This marks the first FDA approval and US launch of a prescription drug using Aptar Pharma’s patented Bidose nasal spray delivery system.
This approval again demonstrates Aptar Pharma’s expertise in developing patient-friendly drug delivery solutions for breakthrough medicines.
Patented Bidose Technology Platform
Aptar Pharma’s Bidose liquid system is designed for local or systemic delivery of drugs. As a robust, primeless, intuitive and easy-to-use device with 360° functionality and precise spray characteristics, the Bidose system provides accurate two-shot nasal drug delivery.
The Aptar Pharma Bidose and Unidose systems offer biotech and pharmaceutical companies effective and reliable intra-nasal delivery platforms for a variety of medicines including potential life-saving treatments and treatments of severe conditions.
This nasal product platform can enhance brand image via an elegant and intuitive design while limiting the volume of drug accessible to patients. The devices can also integrate wireless connectivity technologies.
Accelerated Development Support via Aptar Pharma Services
This breakthrough therapy approval is an example of a Combination Product, and benefited from Aptar Pharma’s Services offering, a comprehensive portfolio of stage-specific packages designed to proactively address regulatory needs to accelerate approval.
Leveraging its extensive value-adding capabilities including lab and analytical services, proven regulatory expertise - with dedicated Regulatory Affairs experts and fast approval data packages - and customized drug delivery solutions, Aptar Pharma’s Services can enable an expedited approval and launch in the competitive pharmaceutical space.
“We are pleased that Aptar Pharma’s Bidose nasal delivery device has been approved by the FDA for this breakthrough therapy in the field of depression,” explained Gael Touya, President, Aptar Pharma. “This project marks close to a 10-year customer collaboration and once again demonstrates Aptar Pharma’s ability to develop and launch complex drug delivery systems worldwide.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance